

### Male and Female

### Male

### Female

Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)
All Sites	449.2	478.2	457.4 ▲▼	3,914	All Sites	487.9	518.1	479.3 ▼	1,969	All Sites	423.2	453.3	449.5 ▲	1,945
Lung and Bronchus	56.3	58.8	58.5	527	Prostate	109.8	122.1	98.8 ▼▼	453	Breast	128.0	136.0	132.6	569
Melanoma of the Skin	22.9	21.1	37.4 ▲▲	305	Lung and Bronchus	64.0	64.8	64.0	269	Lung and Bronchus	50.3	54.7	54.2 ▲	258
Colon and Rectum	37.6	37.6	34.4 ▼▼	289	Melanoma of the Skin	29.1	26.6	43.1 ▲▲	170	Uterus	27.6	31.6	33.7 ▲	160
Urinary Bladder	19.4	22.7	22.8 ▲	204	Colon and Rectum	43.0	43.0	39.1 ▼▼	153	Colon and Rectum	33.0	33.1	30.2 ▼▼	136
Non-Hodgkin Lymphoma	19.0	20.9	19.0 ▼	162	Urinary Bladder	33.5	39.2	37.9 ▲	153	Melanoma of the Skin	18.3	17.2	33.4 ▲▲	135
Kidney	17.3	16.8	15.7 ▼	133	Non-Hodgkin Lymphoma	22.9	25.2	22.6 ▼	89	Non-Hodgkin Lymphoma	15.7	17.4	16.0	73
Pancreas	13.2	14.3	12.4 ▼	111	Kidney	23.5	23.4	20.7 ▼	84	Thyroid	20.3	26.4	21.9 ▼	72
Oral Cavity/Throat	12.0	11.9	12.5	108	Oral Cavity/Throat	18.2	17.7	19.0	79	Pancreas	11.6	12.6	11.3	54
Leukemia	14.1	15.1	12.3 ▼▼	100	Leukemia	17.9	19.5	15.8 ▼	60	Urinary Bladder	8.4	10.3	10.5 ▲	52
Thyroid	13.8	18.2	14.9 ▼	100	Pancreas	15.1	16.3	13.7 ▼	57	Kidney	12.0	11.3	11.3	49
Brain/Nervous System	6.4	6.8	7.2	52	Esophagus	7.9	8.4	9.3 ▲	39	Leukemia	11.0	11.6	9.5 ▼	41
Myeloma	7.0	7.4	5.8 ▼▼	51	Liver	13.1	13.1	8.5 ▼▼	38	Ovary	10.4	11.1	9.0 ▼	39
Esophagus	4.5	4.9	5.5 ▲	50	Stomach	8.5	9.8	7.6 ▼	31	Oral Cavity/Throat	6.5	6.8	6.7	28
Liver	8.6	8.4	5.5 ▼▼	50	Brain/Nervous System	7.6	8.1	8.5	30	Brain/Nervous System	5.4	5.8	5.9	22
Stomach	6.4	7.3	5.6 ▼	47	Myeloma	8.6	9.2	6.9 ▼▼	29	Myeloma	5.7	6.0	4.7 ▼	22
Larynx	3.1	3.0	3.1	27	Thyroid	7.2	9.7	7.8 ▼	28	Stomach	4.6	5.2	3.7 ▼	16
Hodgkin Lymphoma	2.6	3.1	2.6	17	Testis	5.7	6.2	7.5 ▲	22	Cervix	7.7	7.0	4.8 ▼▼	16
					Larynx	5.3	5.3	4.7	20	Liver	4.8	4.4	2.8 ▼▼	12
					Hodgkin Lymphoma	2.9	3.5	2.9	9	Esophagus	1.8	2.0	2.2	11
										Hodgkin Lymphoma	2.3	2.8	2.4	8
										Larynx	1.2	1.2	1.7	7

▲ Statistically higher than the U.S. rate. ▲ Statistically higher than the N.E. rate.  
▼ Statistically lower than the U.S. rate. ▼ Statistically lower than the N.E. rate.

**TECHNICAL NOTES:** Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Incidence rates exclude in situ carcinomas except urinary bladder. Incidence data were coded using the International Classification of Disease for Oncology (ICD-O) coding system. Vermont cases include Vermont residents only. The Vermont and U.S. incidence rates are based on the Vermont Cancer Registry, Vermont Department of Health (1994-2019) and the NPCR and SEER Incidence - U.S. Cancer Statistics Public Use Database, 2021 submission (2001-2019), United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2022. Available at [www.cdc.gov/cancer/uscs/public-use](http://www.cdc.gov/cancer/uscs/public-use). Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont. A reporting delay by Department of Veterans Affairs (VA) has resulted in incomplete reporting of VA hospital cases in 2011-2014, 2016-2019.

**COPYRIGHT INFORMATION:** All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

**SUGGESTED CITATION:** Age Adjusted Cancer Incidence Rates, 2015-2019, Vermont Department of Health, Burlington, VT, 2022.

**ACKNOWLEDGEMENT:** This publication was supported by the Grant or Cooperative Agreement CDC-RFA-DP17-1701, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

**For more information:** Email [Michael.Flaherty@Vermont.gov](mailto:Michael.Flaherty@Vermont.gov) or visit [healthvermont.gov/cancer](http://healthvermont.gov/cancer)



Male and Female

Male

Female

Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)
All Sites	152.4	148.9	158.2 ▲▲	1,389	All Sites	181.4	176.5	186.9 ▲	737	All Sites	131.1	129.8	136.7 ▲▲	652
Lung and Bronchus	36.7	35.4	38.0 ▲	341	Lung and Bronchus	44.5	42.0	43.6	178	Lung and Bronchus	30.7	30.5	33.5 ▲▲	163
Colon and Rectum	13.4	12.5	14.3 ▲	122	Prostate	18.9	18.0	19.6	71	Breast	19.9	18.9	17.5 ▼	83
Pancreas	11.1	11.4	10.9	98	Colon and Rectum	16.0	14.8	15.7	61	Colon and Rectum	11.3	10.7	13.1 ▲▲	62
Leukemia	6.1	6.0	6.0	51	Pancreas	12.7	13.1	12.2	50	Pancreas	9.6	10.0	9.8	48
Liver	6.6	6.0	5.4 ▼	49	Esophagus	6.8	7.2	8.8 ▲▲	37	Ovary	6.5	6.6	6.0	28
Non-Hodgkin Lymphoma	5.3	5.3	5.6	48	Liver	9.7	9.0	7.8 ▼	34	Uterus	5.0	5.6	5.7	27
Brain/Nervous System	4.4	4.4	5.7 ▲▲	46	Urinary Bladder	7.3	7.6	8.4	31	Leukemia	4.6	4.5	4.6	22
Esophagus	3.9	4.0	4.9 ▲▲	45	Leukemia	8.2	8.2	7.8	29	Brain/Nervous System	3.6	3.5	4.8 ▲▲	21
Urinary Bladder	4.2	4.4	4.8	42	Non-Hodgkin Lymphoma	6.9	6.9	7.3	27	Non-Hodgkin Lymphoma	4.0	4.1	4.4	21
Kidney	3.6	3.1	3.7 ▲	34	Brain/Nervous System	5.4	5.4	6.6 ▲	25	Liver	4.1	3.6	3.2	15
Myeloma	3.2	3.0	3.1	27	Kidney	5.2	4.5	5.7 ▲	24	Myeloma	2.5	2.4	2.4	12
Oral Cavity/Throat	2.5	2.2	2.5	23	Oral Cavity/Throat	3.9	3.5	3.7	16	Urinary Bladder	2.1	2.2	2.3	11
Melanoma of the Skin	2.2	2.0	2.2	20	Myeloma	4.0	3.8	3.8	15	Kidney	2.2	1.9	2.2	10
Stomach	2.9	2.9	2.2 ▼▼	19	Stomach	3.9	4.0	3.4	13	Esophagus	1.4	1.5	1.6	8
Larynx	0.9	0.9	0.9	8	Melanoma of the Skin	3.2	3.0	3.1	13	Oral Cavity/Throat	1.4	1.2	1.5	7
Thyroid	0.5	0.5	0.5	5	Larynx	1.6	1.6	1.5	6	Melanoma of the Skin	1.4	1.3	1.5	7
Hodgkin Lymphoma	0.3	0.3	0.2	2	Thyroid	0.5	0.5	0.7	3	Stomach	2.1	2.1	1.2 ▼▼	6
					Testis	0.3	0.2	--	<1	Cervix Uteri	2.2	1.7	1.0 ▼	4
					Hodgkin Lymphoma	0.4	0.3	--	<1	Larynx	0.4	0.3	0.3	2
										Thyroid	0.5	0.5	0.3	1
										Hodgkin Lymphoma	0.2	0.2	--	<1

▲ Statistically higher than the U.S. rate. ▲ Statistically higher than the N.E. rate.  
▼ Statistically lower than the U.S. rate. ▼ Statistically lower than the N.E. rate.

**TECHNICAL NOTES:** Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (19 age groups - Census P25-1130) and exclude basal cell and squamous cell skin cancers. Mortality data were coded using the International Classification of Disease Tenth Revision (ICD-10) coding system. Vermont deaths include Vermont residents only. -- Rates based on 5 or fewer deaths are not individually calculated. The Vermont and the U.S. mortality rates are based on the Vermont Vital Statistics System, Vermont Department of Health (1994-2019) and the Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2019) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released June 2022. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont.

**COPYRIGHT INFORMATION:** All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

**SUGGESTED CITATION:** Age Adjusted Cancer Mortality Rates, 2015-2019, Vermont Department of Health, Burlington, VT, 2022.

**ACKNOWLEDGEMENT:** This publication was supported by the Grant or Cooperative Agreement CDC-RFA-DP17-1701, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

**For more information:** Email [Michael.Flaherty@Vermont.gov](mailto:Michael.Flaherty@Vermont.gov) or visit [healthvermont.gov/cancer](http://healthvermont.gov/cancer)